Eli Lilly and Company LLY NYSE

Eli Lilly and Company (LLY) reported total assets of $112.48B and total liabilities of $85.94B for fiscal year 2025, resulting in total equity of $26.54B.

The company held $7.27B in cash and short-term investments. Total debt stood at $42.5B, with net debt of $35.34B. The Debt-to-Equity (D/E) ratio was 1.6 (leveraged).

Current ratio is 1.58, indicating strong short-term liquidity. Interest coverage is 37.3x (strong).

Criteria supported by this page:

• HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (100/100) — Total assets $112.48B and equity $26.54B support the company's competitive scale
• VALUE (47/100) — Debt-to-Equity 1.6 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 86/100 with 5/7 criteria passed.

JNJ

Johnson & Johnson

$240.10

+0.90%

ABBV

AbbVie Inc.

$210.32

+1.86%

AZN

AstraZeneca PLC

$204.38

+1.06%

MRK

Merck & Co., Inc.

$119.96

-0.16%

NVS

Novartis AG

$153.38

-0.71%

AMGN

Amgen Inc.

$350.95

+0.32%

NVO

Novo Nordisk A/S

$39.32

+3.53%

GILD

Gilead Sciences, Inc.

$140.45

+1.02%